Mechanisms of cardiovascular risk reduction with ramipril: Insights from HOPE and HOPE substudies

European Heart Journal, Supplement

Volumn 5, Issue A, 2003, Pages

  Lonn, E ^b   Gerstein, H C ^c   Smieja, M ^c   Mann, J F E ^a   Yusuf, S ^c  

^a UNIVERSITY OF MUNICH   (Germany)

^b HAMILTON GENERAL HOSPITAL   (Canada)

^c NONE

Author keywords

ACE inhibitors; Atherosclerosis; Cariovascular disease; HOPE; Ramipril; SECURE

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; QUINAPRIL; RAMIPRIL;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; FOLLOW UP; GLUCOSE METABOLISM; HEART FUNCTION; HEART PROTECTION; HUMAN; INFLAMMATION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK ASSESSMENT;

EID: 0037251186     PISSN: 1520765X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1520-765X(03)90063-0     Document Type: Conference Paper

References (39)

1. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G, for the Heart Outcomes Prevention Evaluation Study Investigators. Effect of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
2. Dzau V, Berstein M, Celermeier D, et al. Pathophysiologic and therapeutic importance of tissue ACE: a consensus report. Cardiovasc Drugs Ther 2002; 16: 149-60.
3. Sleight P, Yusuf S, Pogue J, Tsuyuki R, Diaz R, Probstfield J. Blood pressure reduction and cardiovascular risk in the HOPE study. Lancet 2001; 358: 2130-1.
4. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and of vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation 2001; 103: 919-25.
5. Simon A, Gariepy J, Chironi G, Megnien J-L, Levenson J. Intimamedia thickness: a new tool for diagnosis and treatment of cardiovascular risk. J Hypertens 2001; 20: 159-69.
6. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990; 15: 327-31.
7. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J Cardiovasc Pharmacol 1990; 15 Suppl. 5: S65-72.
8. Hayek T, Kaplan M, Raz A, Keidar S, Coleman R, Aviram M. Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis. Atherosclerosis 2002; 161: 65-74.
9. Espeland MA, Craven TE, Riley WA, Corson J, Romant A, Furberg CD. Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thickness. Asymptomatic Carotid Artery Progression Study Research Group. Stroke 1996; 27: 480-5.
10. Bosch J, Yusuf S, Pogue J, et al., for the HOPE Investigators. Use of ramipril in preventing stroke: double blind randomised trial. BMJ 2002; 324: 699-702.
11. Cashin-Hemphill L, Holmvang G, Chan RC, Pitt B, Dinsmore RE, Lees RS, for the QUIET Investigators. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. Quinapril Ischemic Event Trial (QUIET). Am J Cardiol 1999; 83: 43-7.
12. Mancini GBJ, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996; 94: 258-65.
13. Teo KK, Burton JR, Buller CE, et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000; 102: 1748-54.
14. MacMahon S, Sharpe N, Gamble G, et al., for the PART-2 Collaborative Research Group. Randomized, placebo-controlled trial of the angiotensin converting enzyme inhibitor, ramipril, in patients with coronary or occlusive arterial disease. Prevention of Atherosclerosis with Ramipril Trial (PART-2). J Am Coll Cardiol 2000; 36: 438-43.
15. Hosomi N, Mizushige K, Ohyama H, et al. Angiotensin-converting enzyme inhibition with enalapril slows progressive intimamedia thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke 2001; 32: 1539-45.
16. Gerstein HC, Mann JFE, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 342: 154-60.
17. The Heart Outcomes Prevention Evaluation (HOPE) Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
18. Mann JFE, Gerstein HC, Yi Q, et al. Development of renal disease in people at high cardiovascualr risk. J Am Soc Nephrol 2003; in press
19. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
20. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-72.
21. Smieja M, Yusuf S, Lonn E, et al. Inflammatory markers and subsequent cardiovascular events in the HOPE trial. Circulation 2001; 17(Suppl II): II-791. Abstract 11363.
22. Gerstein H, Malmberg K, Capes S, Yusuf S. Cardiovascular diseases. In: Gerstein H, Haynes RB, eds. Evidence-based diabetes care. Ontario, Canada: BC Decker Inc; 2001.
23. Haffner SM, Miettinen H. Insulin resistance implications for type 2 diabetes mellitus and coronary heart disease. Am J Med 1997; 103: 152-62.
24. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-73.
25. Pollare T. Insulin sensitivity and blood lipids during antihypertensive treatment with special reference to ACE inhibition. J Diabet Complications 1990; 4: 75-8.
26. Yusuf S, Gerstein H, Hoogwerf B, Pogue J, Bosch J, Wolffenbuttel BHR, Zinman B, for the HOPE Study Investigators. Ramipril and the development of diabetes. JAMA 2001; 286: 1882-5.
27. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomized trial. Lancet 1999; 353: 611-6.
28. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
29. Lonn E, Weitz J, McQueen M, Dzavik V, Gerstein H, Yusuf S. Metabolic and hematologic effects of ramipril in the HOPE trial. Circulation 2000; 102 (Suppl II): II-408. Abstract 1127.
30. Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease: the Framingham Study. Ann Intern Med 1970; 72: 813-22.
31. Levy D, Garrison MS, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-6.
32. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B. Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 1994; 90(4): 2056-69.
33. Dahlöf B. Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5: 95-110.
34. St. John Sutton M, Pfeffer MA, Moye L, et al. Cardiovascular death and left ventricular remodeling two years after myocardial infarction: baseline predictors and impact of long-term use of captopril: information from the Survival and Ventricular Enlargement (SAVE) trial. Circulation 1997; 96(10): 3294-9.
35. Linz W, Scholkens BA, Ganten D. Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats. Clin Exp Hypertens A 1989; 11: 1325-50.
36. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-65.
37. McDonald KM, Garr M, Carlyle PF, et al. Relative effects of alpha 1-adrenoceptor blockade, converting enzyme inhibitor therapy, and angiotensin II subtype 1 receptor blockade on ventricular remodeling in the dog. Circulation 1994; 90(6): 3034-46.
38. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor, ramipril. Circulation 2001; 104: 1615-21.
39. Lonn E, Shaikholeslami R, Yi Q, Bosch J, Magi A, Yusuf S. Effects of ramipril on left ventricular mass and function in normotensive patients with preserved left ventricular function. A substudy of HOPE. J Am Coll Cardiol 2001; 37(Suppl A): 165A.